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Abstract
Background: The regulation of fibroblast growth factor-23 (FGF23) secretion in patients with chronic kidney
disease (CKD) is incompletely understood. An in vitro study showed that metabolic acidosis increased FGF23 in
mouse bone. The objective of this study is to evaluate the effect of oral sodium bicarbonate on circulating FGF23 levels
in patients with CKD.
Methods: This was a single-blind pilot study. Twenty adults with estimated glomerular filtration rate between
15–45 mL/min/1.73 m2 and serum bicarbonate between 20–24 mEq/L were treated with placebo for 2 weeks,
followed by increasing doses of oral sodium bicarbonate (0.3, 0.6 and 1.0 mEq/kg/day) in 2 week intervals for a
total of 6 weeks. C-terminal FGF23 levels were measured at the initial visit, after 2 weeks of placebo and after
6 weeks of bicarbonate therapy. Wilcoxon matched-pairs signed-rank test was used to compare FGF23 before
and after sodium bicarbonate.
Results: After 6 weeks of oral sodium bicarbonate, the median FGF23 increased significantly from 150.9 RU/mL
(IQR 107.7–267.43) to 191.4 RU/mL (IQR 132.6–316.9) (p = 0.048) and this persisted after excluding participants
who received activated vitamin D.
Conclusions: FGF23 increased after short-term oral sodium bicarbonate therapy in patients with CKD and mild
metabolic acidosis. It is unclear whether this was due to the alkalinizing effect of sodium bicarbonate or other factors.
Trial registration: The study was registered at ClinicalTrials.gov (NCT00888290) on April 23, 2009.
Keywords: Metabolic acidosis, Fibroblast growth factor-23, Sodium bicarbonate, Alkali therapy, Mineral
metabolism, Vitamin D
Background
Fibroblast growth factor 23 (FGF23) is a hormone pro-
duced in osteocytes and osteoblasts [1–3]. Its primary
physiological actions are to induce phosphaturia by
down-regulating the type IIA sodium-phosphate co-
transporter in the proximal tubule, reduce systemic
1,25-dihydroxyvitamin D (1,25-OH vitamin D) produc-
tion and inhibit parathyroid hormone (PTH) secretion
[4–7]. Elevated FGF23 levels are associated with multiple
adverse outcomes including kidney disease progression,
cardiovascular events and death [8–12]. The regulation of
FGF23 secretion in patients with chronic kidney disease
(CKD) is incompletely understood.
Since metabolic acidosis stimulates bone resorption
and regulates osteoblast activity and osteoblasts pro-
duce FGF23, metabolic acidosis may regulate FGF23
secretion [13]. Patients with CKD develop chronic
metabolic acidosis due to loss of functioning renal mass
and inability to excrete the acids that are generated
through metabolism of dietary acid precursors. An in
vitro study demonstrated that metabolic acidosis
increased FGF23 concentration and RNA expression in
mouse bone [13]. If metabolic acidosis increases FGF23,
then alkali therapy would be expected to lower FGF23 and
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possibly reduce mortality in patients with CKD. The ef-
fect of alkali therapy on FGF23 regulation has not been
examined in human studies. The objective of this study
is to evaluate the effect of alkali therapy, using oral so-
dium bicarbonate, on circulating FGF23 levels in pa-
tients with CKD. We hypothesized that administration
of sodium bicarbonate would lower FGF23.
Methods
Study population and design
This was a single-blind pilot study, conducted at
Montefiore Medical Center, Bronx, New York. Details
of the population and design were published previ-
ously [14]. Briefly, the study included 20 adults with
estimated glomerular filtration rate (eGFR) between
15–45 mL/min/1.73 m2 and serum bicarbonate be-
tween 20–24 mEq/L. Participants were blinded to
treatment status and investigators were not. After the
initial visit, participants were treated with placebo for
2 weeks, followed by increasing doses of oral sodium
bicarbonate in 2 week intervals for a total of 6 weeks.
The doses of sodium bicarbonate were 0.3, 0.6 and
1.0 mEq/kg per day. Blood and 24-h urine samples
were collected at the initial visit and during the final
2 days of each 2-week interval. Blood and urine sam-
ples were stored at −80 °C.
Data collection and measurement
Serum and urine chemistry values were measured by
routine procedures in the clinical laboratory at Monte-
fiore Medical Center. Serum bicarbonate was measured
using the phosphoenolpyruvate carboxylase method.
Serum and urine creatinine were measured by a modi-
fied kinetic Jaffe reaction. eGFR was calculated using the
CKD Epidemiology Collaboration Equation [15]. Serum
25-OH vitamin D was measured by a validated liquid
chromatography/tandem mass spectrometry analysis.
C-terminal FGF23 was measured using enzyme-linked
immunosorbent assay (Immutopics International) in
the stored specimens. FGF23 was measured at the ini-
tial visit, after 2 weeks of placebo and after 6 weeks of
bicarbonate therapy.
Statistical analyses
Values of variables before sodium bicarbonate were cal-
culated by averaging the values at the initial visit and
after the 2-week placebo. To compare variables before
and after sodium bicarbonate, a paired t-test was used
if there was no violation of test assumptions, and a
Wilcoxon matched-pairs signed-rank test was used if
assumptions were violated. Since activated vitamin D
has been shown to increase FGF23 in patients with
CKD [16, 17], sensitivity analyses were done after exclud-
ing participants who were taking nutritional or activated
vitamin D using Wilcoxon matched-paired signed-rank
tests. To estimate the relationship of FGF23 with other
variables, a linear mixed model was used. Graphical in-
spection of the data suggested a logarithmic transform-
ation of FGF23, and log base 2 transformation was carried
out. Visit time was included as a factor to control for time
variation of the response log-transformed FGF23, and a
subject level random effect was included. Analyses were
performed using STATA 12.1 (StataCorp, Texas) except
the linear mixed models, which were fit using the R func-
tion linear mixed-effect (Venables, W.N. and Ripley, B.D
(2002) “Modern Applied Statistics with S”, 4th Edition,




Enrollment is shown in Fig. 1. Baseline characteristics
of participants are listed in Table 1. The mean age was
63 ± 11 years. Twelve participants (60 %) were female.
Participants were either black or Hispanic. Almost all
had diagnoses of diabetes mellitus or hypertension. The
mean eGFR was 32.9 ± 8.9 ml/min/1.73 m2 with mean
bicarbonate of 23.0 ± 2.4 mEq/L. The median FGF23
was 157.4 RU/mL (Interquartile range [IQR] 90.2-
289.4). Nine participants were receiving vitamin D at
baseline (nutritional vitamin D—ergocalciferol/cholecalcif-
erol [n = 6] or paricalcitol [n = 3]; no other activated vita-
min D were prescribed). Among them, one participant
(participant #3) had paricalcitol dose increased during the
study, and one participant (participant #16) had very high
Fig. 1 Enrollment. Twenty participants were included in the final
analysis. Two completed only 6 weeks of the study and received
2 weeks of placebo and 4 weeks of sodium bicarbonate
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FGF23 at baseline (824.9 RU/mL). None of the partici-
pants received phosphate binders during the study period.
Fifteen participants were receiving diuretics. Two of them
had diuretic dose increased prior to their last visit while
others remained on the same dose throughout the study.
Effect of sodium bicarbonate therapy
After 2-weeks of placebo, there was no significant
change in bicarbonate or FGF23 compared to the initial
visit (Table 2). Therefore, bicarbonate and FGF23 values
before sodium bicarbonate were calculated by averaging
the values at the initial visit and after 2-weeks of pla-
cebo. Eighteen participants received 6 weeks of sodium
bicarbonate, and 2 participants were withdrawn from
the study after receiving 4 weeks of active medication
(Fig. 1). After sodium bicarbonate therapy, there was no
change in eGFR. The mean bicarbonate increased from
22.6 ± 2.3 mEq/L to 25.5 ± 2.2 mEq/L (p < 0.001). No
statistically significant changes were observed in 25-OH
vitamin D, 1,25-OH vitamin D, serum calcium, serum
phosphate, urine calcium, urine phosphate, urine so-
dium, fractional excretion of phosphate or sodium al-
though the p-value was marginally significant for urine
sodium (p = 0.07) (Table 2).
Table 1 Baseline characteristics of participants (n = 20)
Characteristic Value
Age (year) 63 ± 11






Blood pressure (mmHg) 134/70 ± 13/7
eGFR (ml/min per 1.73 m2) 32.9 ± 8.9
Serum bicarbonate (mEq/L) 23.0 ± 2.4
FGF23 (RU/mL) 157.4 (90.2–289.4)
25-OH vitamin D (ng/mL) 36 ± 13
Age, blood pressure, eGFR, serum bicarbonate, 25-OHvitamin D were expressed as
mean ± standard deviation. FGF23 was expressed as median (interquartile range)
Abbreviations: eGFR estimated glomerular filtration rate, FGF23 fibroblast
growth factor-23, RU rack unit, 25-OH vitamin D 25-hydroxyvitamin D
Table 2 Effect of sodium bicarbonate therapy
Initial 2-week placebo p-value
Serum Bicarbonate (mEq/L) 23.0 ± 2.3 22.2 ± 2.8 0.17
FGF23 (RU/mL) 157.4 (90.2–289.4) 161.7 (104.5–245.5) 0.91
Before sodium bicarbonatea After sodium bicarbonate p-value
Systolic blood pressure (mmHg) 131 ± 11 130 ± 14 0.71
Diastolic blood pressure (mmHg) 69 ± 8 70 ± 10 0.66
Serum Bicarbonate (mEq/L) 22.6 ± 2.3 25.5 ± 2.2 < 0.001
eGFR (ml/min per 1.73 m2) 40.6 ± 15.6 40.0 ± 15.1 0.65
FGF23 (RU/mL) 150.9 (107.7–267.43) 191.4 (132.6–316.9) 0.048
25-OH vitamin D (ng/mL) 36 ± 13 37 ± 14 0.60
1, 25-OH vitamin D (pg/mL)c 42 (21–58) 42 (18–57) 0.79
Serum calcium (mg/dL) 9.9 ± 0.5 9.9 ± 0.5 0.39
Serum phosphate (mg/dL) 4.0 ± 0.8 3.9 ± 0.8 0.31
Urine calcium (mg/mg Cr)b 0.03 (0.02–0.04) 0.01 (0.01–0.05) 0.09
Urine phosphate (mg/mg Cr)b 0.47 (0.28–0.61) 0.42 (0.32–0.55) 0.84
Urine sodium (mg/mg Cr)b 2.4 ± 0.7 2.8 ± 1.0 0.07
Fractional excretion of phosphate (%) 18 (14–24) 21 (15–26) 0.22
Fractional excretion of sodium (%) 1.4 (1.1–2.4) 1.6 (1.1–2.2) 0.44
Serum bicarbonate, 25-OH vitamin D, serum calcium, phosphate and urine sodium were expressed as mean ± standard deviation. FGF23, 1,25-OH vitamin D, urine
calcium and phosphate, fractional excretion of phosphate and sodium were expressed in median (interquartile range)
Abbreviations: eGFR estimated glomerular filtration rate, 25-OH vitamin D 25-hydroxyvitamin D, 1,25-OH vitamin D 1,25-dihydroxyvitamin D, FGF23 fibroblast
growth factor-23
aValues of variables for “before sodium bicarbonate” were the mean of values between the initial visit and after 2-week placebo
burine calcium, phosphate and sodium were normalized by dividing urine creatinine. The mean urinary sodium increased from 2.4 ± 0.7 to 2.6 ± 0.9 mg/mg Cr
after excluding 2 participants who had their diuretics dose increased prior to the last visit (p = 0.20)
cOnly 11 participants had 1,25-OHvitamin D level available at before and after 6-week sodium bicarbonate therapy
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FGF23 increased in 14 (70 %) participants. The me-
dian FGF23 increased significantly from 150.9 RU/mL
(IQR 107.7–267.43) to 191.4 RU/mL (IQR 132.6–316.9)
(p = 0.048) (Fig. 2). This finding remained statistically
significant after excluding the 3 participants that were
on paricalcitol (p = 0.009) or after excluding participant
#16, who had a very high FGF23 at baseline (p = 0.01).
The median FGF23 increased after excluding all 9 par-
ticipants on vitamin D or after excluding participant #3,
who had an increased paricalcitol dose during the
study, but it was not statistically significant (p = 0.08 for
both) (Table 3).
Bivariate associations with FGF23
There was no significant association between bicarbon-
ate and FGF23 (log-transformed) (regression coefficient
= −0.032, p = 0.21). There was no significant association
of FGF23 with 25-OH vitamin D, serum calcium, urine
calcium or urine sodium. FGF23 was inversely associated
with 1,25-OH vitamin D (p = 0.005), and positively asso-
ciated with serum and urine phosphate (p = 0.001, 0.02
respectively) (Table 4).
Discussion
This is the first human study evaluating the effect of oral
sodium bicarbonate on the regulation of circulating
FGF23. We found that oral sodium bicarbonate did not
decrease FGF23 in patients with CKD and mild acidosis.
Contrary to our hypothesis, there was a statistically sig-
nificant increase in C-terminal FGF23 levels after 6 weeks
of oral sodium bicarbonate (Fig. 2), and this effect per-
sisted after excluding participants who received activated
vitamin D (Table 3).
The FGF23 levels were similar to the levels reported by
others. The median C-terminal FGF23 was 157.4 RU/mL
(IQR 90.2–289.4) with a mean eGFR of 32.9 ± 8.9 ml/
min/1.73 m2 at the initial visit. In the Chronic Renal
Insufficiency Cohort (CRIC) study, the median C-
terminal FGF23 was 145 RU/mL (IQR 96–239) in pa-
tients with a mean eGFR of 42.8 ± 13.5 ml/min/1.73 m2
[9]. Elevated FGF23 has been linked to several adverse
clinical outcomes in patients with CKD, including kid-
ney disease progression, cardiovascular disease and
death [8–12]. In a cohort of 227 patients with CKD,
FGF23 was an independent predictor of kidney disease
progression after a median of 53 months follow up [10].
Fig. 2 FGF23 before and after sodium bicarbonate therapy (n = 20).
FGF23 before sodium bicarbonate therapy was calculated by averaging
FGF23 at the initial visit and after 2-week placebo. Participant #16
was the outlier
Table 3 Sensitivity analysis after excluding participants on
vitamin D






Yes (n = 9) 217.0 (146.4–353.2)* 327.4 (231.7–410.9) 0.31
No (n = 20) 121.2 (85.1–162.4)* 147.4 (107.0–196.5) 0.08
Taking paricalcitol
Yes (n = 3) 353.2 (98.9–824.9)** 399.1 (327.4–410.9) 0.59
No (n = 17) 146.4 (116.5–217.0)** 185.7 (129.9–238.4) 0.009
Increased paricalcitol dose
Yes (n = 1)c 98.8 399.1 N/A
No (n = 19) 155.5 (116.5–286.5) 186.4 (129.9–306.4) 0.08
Participant #16d
Yes (n = 1) 824.9 410.9 N/A
No (n = 19) 146.4 (98.8–248.3) 186.4 (129.9–306.4) 0.01
FGF23 was expressed in median (interquartile range)
Abbreviation: N/A not applicable
*p-value comparing FGF23 between those taking vitamin D and those not
taking vitamin D = 0.06
**p-value comparing FGF23 between those taking paricalcitol and those not
taking paricalcitol = 0.02
aVariables for “before sodium bicarbonate” were the mean of values between
the initial visit and after 2-week placebo
bVitamin D used included ergocalciferol, cholecalciferol and paricalcitol
cParticipant #3 had paricalcitol dose increased during the study
dParticipant #16 had very a high FGF23 level at baseline
Table 4 Bivariate Association with log-transformed FGF23 (RU/mL)
Regression Coefficient p-value
Serum Bicarbonate (mEq/L) -0.032 0.21
25-OH vitamin D (ng/mL) -0.005 0.45
1, 25-OH vitamin D (pg/mL) -0.012 0.005
Serum calcium (mg/dL) 0.032 0.83
Serum phosphate (mg/dL) 0.282 0.001
Urine calcium (mg/mg Cr) 2.911 0.34
Urine phosphate (mg/mg Cr) 1.274 0.02
Urine sodium (mg/mg Cr) 0.131 0.22
Urine calcium, phosphate and sodium were normalized by dividing by
urine creatinine
Abbreviations: FGF23 fibroblast growth factor-23, RU rack unit, 25-OH vitamin D
25-hydroxyvitamin D1, 25-OH vitamin D 1,25-dihydroxyvitamin D
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Isakova et al. [9] used the data from the CRIC study
and demonstrated that higher FGF23 was independ-
ently associated with a greater risk of death. In our
study, after 6 weeks of oral sodium bicarbonate, the
median FGF23 increased significantly from 150.9 RU/
mL to 191.4 RU/mL. This increase in FGF23 is about
the same order of magnitude as the difference in
FGF23 that was associated with increased mortality in
the CRIC study [9]. In addition, participants only re-
ceived 6 weeks of sodium bicarbonate in our study, but
in clinical practice, patients with CKD are often on so-
dium bicarbonate therapy for several years. Therefore,
the potential effect of sodium bicarbonate on FGF23
could be greater in clinical settings.
There are several explanations for why our findings
differ from the in vitro data observed by Krieger et al.
[13], who found that metabolic acidosis increased
FGF23 protein and RNA expression in cultured neo-
natal mouse calvariae. First, in vitro data may differ
from in vivo due to other unmeasured factors. In an in
vivo study, Leibrock et al. [18] examined the effect of
acidosis induced by ammonium chloride treatment on
the phenotype of klotho-hypomorphic mice, which suffer
from tissue calcification and reduced life span [19, 20].
FGF23 was significantly higher in these mice compared to
wild-type mice, and ammonium chloride treatment sig-
nificantly decreased intact FGF23 [18]. In clinical stud-
ies, Dobre et al. [21, 22] examined the association of
serum bicarbonate with cardiovascular morbidity in
CKD using the CRIC study and found that high bicar-
bonate was associated with greater risk of heart failure
in multivariable analysis including adjustment for diur-
etic use. FGF23 induces hypertrophic growth of cardiac
myocytes in rodents and promotes left ventricular
hypertrophy by activating FGF receptor-4 [23, 24], and
left ventricular hypertrophy is an independent risk fac-
tor for heart failure [25]. If alkali therapy does indeed
increase FGF23, this could contribute to the risk of
heart failure in patients with CKD.
Second, the increased FGF23 might not be induced
by the alkalinizing effect of sodium bicarbonate as we
did not find a statistically significant association be-
tween bicarbonate and FGF23 (Table 4). The associ-
ation between bicarbonate and FGF23 could be falsely
negative due to the small sample size and lack of vari-
ability in bicarbonate levels because of the entry criteria
for the study. Nevertheless, FGF23 could be increased due
to other mechanisms not directly related to the alkaliniz-
ing effect of sodium bicarbonate: 1) sodium bicarbonate
could cause sodium loading; 2) bicarbonate therapy could
result in increased protein intake thus higher dietary phos-
phorus intake and 3) FGF23 might increase with time.
Sodium bicarbonate could increase FGF23 because of
the sodium loading. Alkali therapy is usually administered
as a sodium or potassium salt. Due to the risk of hyper-
kalemia in patients with CKD, the sodium salt is often
preferred. After 6 weeks of sodium bicarbonate, we
found that the mean urinary sodium increased from 2.4
to 2.8 mg/mg Cr (p = 0.07) and the result was similar
after excluding the 2 participants who had their diuretic
dose increased (Table 2). There is no direct evidence on
the effect of dietary sodium on circulating FGF23.
Sodium loading increases urinary calcium excretion
[26–28] as calcium reabsorption depends on the con-
centration gradient created by the reabsorption of
sodium. Increased urinary calcium excretion may de-
crease serum ionized calcium and stimulate PTH release.
PTH can then increase FGF23 by directly stimulating
FGF23 gene expression and indirectly via PTH-mediated
increase in 1, 25-OH vitamin D [29, 30]. Furthermore,
FGF23 has been shown to be involved in renal sodium re-
tention and volume expansion, specifically by regulating
the membrane abundance of the NaCl co-transporter,
thus increasing distal tubular sodium reabsorption [31].
We speculate that this may provide a mechanistic link
between oral sodium bicarbonate, sodium loading and
FGF23.
Bicarbonate therapy could increase FGF23 by increas-
ing dietary protein intake. De Brito-Ashurst et al. [32]
found that compared to the control group, the bicar-
bonate group had higher dietary protein intake and al-
bumin level. Increased dietary phosphorus intake from
protein may then increase FGF23 [33–35]. However, in
our study we found that 6 weeks of sodium bicarbonate
therapy decreased urinary nitrogen excretion as previ-
ously published [14]. Together with the absence of
change in urinary phosphate (Table 2), the speculation
that bicarbonate therapy could increase FGF23 by in-
creasing dietary protein intake is blunted.
FGF23 might also increase with time. However, whether
FGF23 increases in 6 weeks without any intervention or
changes in eGFR is unclear. In a 12-week placebo-
controlled study of ferric citrate involving patients with
CKD stage 3 to 5 [36], intact FGF23 decreased in the
placebo arm from 184 pg/mL [IQR 111–135] to
148 pg/mL [IQR 101–330].
We also accounted for the possible confounding ef-
fect of vitamin D. There was a negative association be-
tween FGF23 and 1,25-OH vitamin D (Table 4). This is
consistent with the data from the CRIC study [9], in
which participants with the lowest quartile of FGF23
had the highest 1,25-OH vitamin D level. The relation-
ship between FGF23 and 1, 25-OH vitamin D is a classic
negative feedback. While 1, 25-OH vitamin D stimulates
FGF23 secretion [37], FGF23 lowers 1,25-OH vitamin D
[4]. The use of activated vitamin D has been shown to
increase FGF23 in patients with CKD [16, 17]. We per-
formed sensitivity analysis after excluding participants
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who were taking vitamin D (Table 3). After excluding
participants who were taking paricalcitol, the change in
FGF23 before and after sodium bicarbonate remained
statistically significant. Also, after excluding partici-
pants who were taking any form of vitamin D or the
participant whose paricalcitol dose was increased, our
results were not qualitatively different.
We found that FGF23 was positively associated with
serum and urine phosphate (Table 4). This is consistent
with the physiological action of FGF23 on phosphate
metabolism [10, 35]. FGF23 is associated with high
serum phosphate [9], but it is unclear whether high
phosphate stimulates FGF23 secretion. Ferrari et al.
[35] found that high-phosphate diet increased FGF23
despite stable serum phosphate. Ito et al. [38] showed
that acute changes in serum phosphate did not modify
FGF23. Infusion of potassium phosphate increased serum
phosphate but did not change FGF23 levels. Our findings
that FGF23 increased without changes in serum phos-
phate (Table 2) suggest that the effect of sodium bicarbon-
ate on FGF23 is not mediated by changes in serum
phosphate levels.
Our study has several limitations, including the small
sample size and lack of a parallel control group. Despite
the small sample size, we found significant associations
of FGF23 levels with 1,25-OH vitamin D and serum and
urine phosphate that were consistent with prior litera-
ture and the underlying physiology. Although there was
no parallel control group, each participant served as his
or her own control by taking placebo for the first
2 weeks. Our findings should also be viewed in the con-
text of the severity of metabolic acidosis in our cohort
and the duration of the study. Patients enrolled had rela-
tively mild metabolic acidosis, and the intervention only
lasted for 6 weeks. The effect of alkali therapy on bone
metabolism might be more pronounced and our result
could have been different had we studied individuals
with more severe acidosis or had the intervention lasted
for a longer period of time. Another limitation is that
metabolic acidosis was defined by serum bicarbonate
levels without other data regarding acid–base status.
This prevents us from fully evaluating the alkalinizing ef-
fect of sodium bicarbonate on FGF23. However, this def-
inition of metabolic acidosis was consistent with the
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative (NKF/KDOQI) guidelines, which sug-
gest treatment of acidosis based on serum bicarbonate
alone [39].
Conclusions
Our pilot study showed that FGF23 levels increased after
short-term oral sodium bicarbonate in patients with
CKD and mild metabolic acidosis. This might not be
due to the alkalinizing effect of sodium bicarbonate, but
at the very least, we observed no reduction in FGF23
that would be predicted based on prior in vitro work
[13]. The NKF/KDOQI suggests maintaining serum bi-
carbonate ≥ 22 mEq/L in order to retard the effects of
metabolic acidosis on progression of CKD and bone loss
(Grade 2B) [39–41], and oral sodium bicarbonate is
often the preferred choice of alkali therapy. It is critical
to elucidate the effect of oral sodium bicarbonate on
FGF23 as higher FGF23 has been associated with sev-
eral adverse outcomes in patients with CKD including
cardiovascular mortality. Long-term placebo-controlled
studies are needed to substantiate our findings.
Abbreviations
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